The Patent Finder

Jiangsu Kanion Pharmaceutical Co., Ltd.

24 patents currently held · Updated Nov 21, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 7 name spellings.

1
Ending by 2030
Jun 2028
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due May 14, 2027
    The maintenance fee for Salts formed by 2-(1-acyloxy-n-pentyl) benzoic acid and basic amino acid or aminoguanidine, and preparation method and application thereof (US 11,814,352) comes due May 14, 2027. Unpaid by Nov 15, 2027, it lapses early.
  • 2 fees due Oct 16 to 28, 2027 · next Oct 16

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 8,067,040Cinnamomi and poria composition and uses thereof
In force
 · USPTO record
In forceUSPTO record
US 9,988,361Anti-enterovirus 71 thiadiazolidine derivative
In force
 · USPTO record
In forceUSPTO record
US 10,227,339Salt Form and Crystal Form of 1,2,5-Thiadiazolidin-1,1-Dioxide, Preparation Method Thereof and Intermediate
In force
 · High confidence
In forceHigh confidence
US 10,633,351Halogenated Compound and Axially Chiral Isomer Thereof
In force
 · High confidence
In forceHigh confidence
US 11,220,525Method for dynamically removing recombinant human nerve growth factor precursor by hydrophobic interaction chromatography
In force
 · USPTO record
In forceUSPTO record
US 11,524,041Ginkgo diterpene lactone composition
In force
 · USPTO record
In forceUSPTO record
US 11,254,635Emodin succinyl ester compound, preparation method therefor and application thereof
In force
 · USPTO record
In forceUSPTO record
US 11,564,904Gingko diterpene lactone composition
In force
 · USPTO record
In forceUSPTO record
US 11,299,548Gene combination capable of high-efficiency expression of recombinant human nerve growth factor
In force
 · USPTO record
In forceUSPTO record
US 11,352,331Crystal and Salt of 4-(NAPHTHALEN-1-YL)-4H-1,2,4-Triazole Compound and Preparation Method Therefor
In force
 · High confidence
In forceHigh confidence
10 of 24 patents shown.
Pro members see all 24.
Pro members: see all 24 patents
Also on record, not counted in the 24: 1 lapsed for an unpaid fee · 6 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

2 pending · 1 abandoned · 6 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited